help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0794
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/11/6323    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rogers, A.
Right arrow Articles by Eastell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogers, A.
Right arrow Articles by Eastell, R.
Related Collections
Right arrow Calcium and Bone Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 11 6323-6331
Copyright © 2005 by The Endocrine Society

REVIEW

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Angela Rogers and Richard Eastell

Academic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, United Kingdom

Address all correspondence and requests for reprints to: Dr. Angela Rogers, Clinical Sciences Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, United Kingdom. E-mail: angela.rogers{at}sheffield.ac.uk.

Context: The discovery of the receptor activator for nuclear factor {kappa}B (RANK) ligand (RANKL)/RANK signaling pathway has marked a major advance in our understanding of the mechanisms controlling osteoclastogenesis. RANKL, expressed by preosteoblasts and stromal cells, binds to RANK, expressed by cells of the osteoclast lineage, inducing a signaling cascade leading to the differentiation and fusion of osteoclast precursor cells and stimulating the activity of the mature osteoclast. The effects of RANKL are counteracted by osteoprotegerin (OPG), a soluble neutralizing decoy receptor.

Evidence: This paper reviews the literature surrounding the use of circulating OPG and soluble RANKL (sRANKL) measurements and assesses their potential as markers of bone disease. Original clinical and basic research articles and reviews were identified using a Pubmed search strategy (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) and cover the time period up until January 2005. Search terms osteoprotegerin, OPG, RANK, RANKL, and RANK ligand were used alone and in combination with bone, osteoporosis, and disease.

Evidence Synthesis: Assays for detecting OPG and sRANKL in the circulation in humans have been developed, and differences in the circulating concentrations of OPG and sRANKL have been observed in different disease states. There are, however, some inconsistencies in study outcome. These may relate to differences in study design, methodology, and other unknown factors influencing the variability of these measurements.

Conclusions: The clinical utility of serum OPG and sRANKL measurements as markers of disease activity requires additional investigation. In particular, rigorous testing of assays and identification of the sources of measurement variability are required.




This article has been cited by other articles:


Home page
 CJASNHome page
S. A. Gomes, L. M. dos Reis, I. L. Noronha, V. Jorgetti, and I. P. Heilberg
RANKL Is a Mediator of Bone Resorption in Idiopathic Hypercalciuria
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1446 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M K. Shea, G. E Dallal, B. Dawson-Hughes, J. M Ordovas, C. J O'Donnell, C. M Gundberg, J. W Peterson, and S. L Booth
Vitamin K, circulating cytokines, and bone mineral density in older men and women
Am. J. Clinical Nutrition, August 1, 2008; 88(2): 356 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Speer, B. Cs. Fekete, T. E. H. Othmane, T. Szabo, J. Egresits, E. Fodor, I. Kiss, A. G. Logan, J. Nemcsik, A. Szabo, et al.
Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients
Nephrol. Dial. Transplant., May 13, 2008; (2008) gfn242v2.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. J. Samelson, K. E. Broe, S. Demissie, T. J. Beck, D. Karasik, S. Kathiresan, and D. P. Kiel
Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1789 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis
Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide
Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
P. Garnero
New Biochemical Markers of Bone Turnover
IBMS BoneKEy, March 1, 2008; 5(3): 84 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. J. Suva, E. Hartman, J. D. Dilley, S. Russell, N. S. Akel, R. A. Skinner, W. R. Hogue, U. Budde, K. I. Varughese, T. Kanaji, et al.
Platelet Dysfunction and a High Bone Mass Phenotype in a Murine Model of Platelet-Type von Willebrand Disease
Am. J. Pathol., February 1, 2008; 172(2): 430 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Vega, N. M. Maalouf, and K. Sakhaee
The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. I Botella-Carretero, F. Alvarez-Blasco, J. L. S. Millan, and H. F Escobar-Morreale
Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women
Eur. J. Endocrinol., May 1, 2007; 156(5): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Stern, G. A Laughlin, J. Bergstrom, and E. Barrett-Connor
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor {kappa}B legend with bone mineral density in older adults: the Rancho Bernardo Study
Eur. J. Endocrinol., May 1, 2007; 156(5): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Dovio, B. Allasino, E. Palmas, M. Ventura, A. Pia, L. Saba, E. Aroasio, M. Terzolo, and A. Angeli
Increased Osteoprotegerin Levels in Cushing's Syndrome Are Associated with an Adverse Cardiovascular Risk Profile
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1803 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. C. Hofbauer, M. Schoppet, M. Christ, J. Teichmann, and U. Lange
Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis
Rheumatology, October 1, 2006; 45(10): 1218 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
D. Granchi, A. Pellacani, M. Spina, E. Cenni, L. M. Savarino, N. Baldini, and A. Giunti
Serum Levels of Osteoprotegerin and Receptor Activator of Nuclear Factor-{kappa}B Ligand as Markers of Periprosthetic Osteolysis
J. Bone Joint Surg. Am., July 1, 2006; 88(7): 1501 - 1509.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society